Importance Emerging evidence suggests that progression independent of relapse activity
(PIRA) is a substantial contributor to long-term disability accumulation in relapsing-remitting …

Importance Early treatment initiation in multiple sclerosis (MS) is crucial in preventing
irreversible neurological damage and disability progression. The current assessment of …

Multiple sclerosis (MS) is a chronic disease of the central nervous system with a global
prevalence of more than 2 million cases worldwide 1 and nearly one million cases in the US …

The emergence of high-efficacy therapies for multiple sclerosis (MS), which target
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …

Multiple sclerosis (MS) is a chronic and progressive neurological disorder impacting
physical, cognitive, and psychosocial health. The disease course, severity, and presence of …

Multiple sclerosis (MS) is a highly heterogeneous disease involving a combination of
inflammation, demyelination, and CNS injury. It is the leading cause of non-traumatic …

Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …

Objective Currently, 233 genetic loci are known to be associated with susceptibility to
multiple sclerosis (MS). Two independent pivotal severity genome‐wide association studies …

Background: The MS disease-modifying therapies (DMTs) prescribing landscape in
Australia have changed over time. Objectives: This study evaluated the utilisation and cost …